Saturday, September 21, 2024

FDA Approves Pivya (pivmecillinam) for the Treatment of Uncomplicated Urinary Tract Infections

›
Today, the U.S. Food and Drug Administration approved Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated ur...
Friday, September 20, 2024

FDA Approves Voydeya (danicopan) as Add-On Therapy for the Treatment of Extravascular Hemolysis in Paroxysmal Nocturnal Hemoglobinuria

›
Voydeya   (danicopan) has been approved in the US as an add-on therapy to eculizumab or eculizumab for the treatment of extravascular hemoly...
Wednesday, September 18, 2024

FDA Approves Vafseo (vadadustat) for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis

›
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney dise...
Tuesday, September 17, 2024

FDA Approves Duvyzat (givinostat) for Duchenne Muscular Dystrophy

›
Italfarmaco S.p.A.  announced today that the  U.S. Food and Drug Administration (FDA)  has approved Duvyzat™ (givinostat), a novel histone d...
Monday, September 16, 2024

FDA Approves Opsynvi (macitentan and tadalafil) for Adults with Pulmonary Arterial Hypertension

›
Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved Opsynvi ®  – a single-tablet combination...
Friday, September 13, 2024

FDA Approves Rezenopy (naloxone hydrochloride) Nasal Spray for the Emergency Treatment of Opioid Overdose

›
The U.S. Food and Drug Administration has approved Rezenopy (naloxone hydrochloride) nasal spray 10 mg for emergency treatment of known or s...
Thursday, September 12, 2024

FDA Approves Tryvio (aprocitentan) for the Combination Treatment of Resistant Hypertension

›
Idorsia Pharmaceuticals U.S. Inc. announced the US Food and Drug Administration (FDA) approval of  Tryvio™ (aprocitentan) for the treatment ...
Wednesday, September 11, 2024

FDA Grants Accelerated Approval for Rezdiffra (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH)

›
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohe...
Tuesday, September 10, 2024

FDA Approves Xolremdi (mavorixafor) for Use in Patients with WHIM Syndrome

›
X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced ...

FDA Approves Exblifep (cefepime/enmetazobactam) for the Treatment of Complicated Urinary Tract Infections,

›
Allecra Therapeutics (“Allecra”), a biopharmaceutical company developing novel therapies to combat antibiotic resistance, announced today th...
Monday, September 9, 2024

FDA Approves Fruzaqla (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

›
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved  Fruzaqla ™ (fruquintinib), an oral...
Friday, September 6, 2024

Salt Substitutes Help Prevent High Blood Pressure

›
Replacing regular salt with a salt substitute can reduce high blood pressure in older adults, a new study has found. Older adults who use a ...